ArticleBMC medicine2022

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.

Wei Nie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.